Search results for "Interleukin-12"

showing 10 items of 84 documents

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.

2021

Abstract Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer and in 24 patients with primary HER2-positive breast cancer undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or fecal microbiota transplantation from antibiotic-treated donors. Modulation of the intestinal microbiota was reflected in tumors by impaired recruitment of CD4+ T cells and granzyme B–posi…

0301 basic medicineCD4-Positive T-LymphocytesCancer ResearchReceptor ErbB-2medicine.medical_treatmentGut floraGranzymesMice0302 clinical medicineAntineoplastic Agents ImmunologicalTrastuzumabTumor Microenvironmentskin and connective tissue diseasesNeoadjuvant therapybiologyFecal Microbiota TransplantationInterleukin-12Neoadjuvant TherapyAnti-Bacterial AgentsTreatment OutcomeOncology030220 oncology & carcinogenesisStreptomycinCytokinesGut microbiota trastuzumab breast cancerFemaleTaxoidsmedicine.drugBridged-Ring CompoundsBreast NeoplasmsSettore MED/08 - Anatomia PatologicaNitric Oxide03 medical and health sciencesImmune systemBreast cancerVancomycinmedicineAnimalsHumansCyclophosphamideImmunity Mucosalbusiness.industryLachnospiraceaeDendritic cellDendritic CellsTrastuzumabbiology.organism_classificationmedicine.diseaseGastrointestinal Microbiome030104 developmental biologyGranzymeDoxorubicinImmune Systembiology.proteinCancer researchInterferonsbusinessCancer research
researchProduct

Localized Interleukin-12 for Cancer Immunotherapy

2020

Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Unfortunately, IL-12's remarkable antitumor efficacy in preclinical models has yet to be replicated in humans. Early clinical trials in the mid-1990's showed that systemic delivery of IL-12 incurred dose-limiting toxicities. Nevertheless, IL-12's pleiotropic activity, i.e., its ability to engage multiple effector mechanisms and reverse tumor-induced immunosuppression, continues to entice cancer researchers. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_treatmentDrug CompoundingImmunologyGenetic Vectorsinterleukin-12 (IL-12)Antineoplastic AgentsReviewBioinformatics03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsintratumoral administrationTumor MicroenvironmentImmunology and AllergyMedicineAnimalsHumansTumor microenvironmentDrug Carrierscancer immunotherapyAntitumor immunitybusiness.industryGene Transfer TechniquesCancerImmunotherapyGenetic Therapymedicine.diseaseInterleukin-12Clinical trialcytokine delivery system030104 developmental biologyTreatment OutcomeInterleukin 12Cancer vaccineImmunotherapybusinesslcsh:RC581-607cancer vaccinelocalized delivery030215 immunologyFrontiers in Immunology
researchProduct

Lung CD11c+ cells from mice deficient in Epstein-Barr virus-induced gene 3 (EBI-3) prevent airway hyper-responsiveness in experimental asthma

2007

Epstein-Barr virus-induced gene (EBI)-3 codes for a soluble type 1 cytokine receptor homologous to the p40 subunit of IL-12 that is expressed by antigen-presenting cells following activation. Here, we analyzed the functional role of EBI-3 in a murine model of asthma associated with airway hyper-responsiveness (AHR) in ovalbumin-sensitized mice. Upon allergen challenge, EBI-3-/- mice showed less severe AHR, decreased numbers and degranulation of eosinophils and a significantly reduced number of VCAM-1+ cells in the lungs as compared to wild-type littermates. We thus analyzed lung CD11c+ cells before and after allergen challenge in these mice and found that before allergen challenge, lung CD1…

Adoptive cell transferMyeloidCell TransplantationImmunologyVascular Cell Adhesion Molecule-1CD11cCD8-Positive T-LymphocytesBiologyMinor Histocompatibility AntigensInterferon-gammaMiceImmune systemmedicineAnimalsImmunology and AllergyReceptors CytokineLungCell ProliferationMice KnockoutLungTumor Necrosis Factor-alphaEffectorDegranulationInterferon-alphaDendritic CellsSTAT4 Transcription Factorrespiratory systemInterleukin-12AsthmaCD11c AntigenInterleukin-10respiratory tract diseasesEosinophilsMice Inbred C57BLmedicine.anatomical_structureImmunologyInterleukin-4Bronchial HyperreactivityInterleukin-5T-Box Domain ProteinsCytokine receptorBronchoalveolar Lavage FluidEuropean Journal of Immunology
researchProduct

Rapid High Efficiency Sensitization of CD8+ T Cells to Tumor Antigens by Dendritic Cells Leads to Enhanced Functional Avidity and Direct Tumor Recogn…

2003

Abstract Myeloid-origin dendritic cells (DCs) can develop into IL-12-secreting DC1 or non-IL-12-secreting DC2 depending on signals received during maturation. Through rapid culture techniques that prepared either mature, CD83+ DC1 or DC2 from CD14+ monocytes in only 2 days followed by a single 6–7 day DC-T cell coculture, we sensitized normal donor CD8+ T cells to tumor Ags (HER-2/neu, MART-1, and gp100) such that peptide Ag-specific lymphocytes constituted up to 16% of the total CD8+ population. Both DC1 and DC2 could sensitize CD8+ T cells that recognized peptide-pulsed target cells. However, with DC2, a general decoupling was observed between recognition of peptide-pulsed T2 target cells…

AdultCytotoxicity ImmunologicMaleReceptor ErbB-2CD8 AntigensT cellImmunologyAntigen presentationEpitopes T-LymphocyteStreptamerCD8-Positive T-LymphocytesBiologyLymphocyte ActivationInterleukin 21MART-1 AntigenAdjuvants ImmunologicAntigens NeoplasmT-Lymphocyte SubsetsCell Line TumorCell AdhesionmedicineHumansImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellMelanomaCells CulturedAntigen PresentationMembrane GlycoproteinsCell DifferentiationDendritic CellsInterleukin-12Peptide FragmentsNeoplasm ProteinsCell biologymedicine.anatomical_structureCulture Media ConditionedImmunologyInterleukin 12FemaleImmunizationgp100 Melanoma AntigenThe Journal of Immunology
researchProduct

Interleukin-12 release by mitogen-stimulated mononuclear cells in the elderly.

1998

Abstract Defects involving cellular expression of activation molecules, cell mediated immune response and natural killer (NK) activity are commonly observed in the elderly. Herein, data are reported on the evaluation of IL-12 production by old subjects. IL-12 is, actually, considered the key molecule for the induction of a T helper 1 (Th1) -type and NK response. IL-12 production from old subjects peripheral blood mononuclear cells (PBMNC) was evaluated using T-independent (bacterial lipopolysaccharide, LPS) or -dependent (phytoemagglutinin, PHA; immobilized anti-CD3 monoclonal antibodies, anti-CD3) mitogens. The IL-12 production after LPS stimulation was not reduced in cultures from old sub…

AdultLipopolysaccharidesMalemedicine.medical_specialtyAgingLipopolysaccharidemedicine.drug_classmedicine.medical_treatmentCD40 LigandStimulationBiologyMonoclonal antibodyPeripheral blood mononuclear cellchemistry.chemical_compoundImmune systemInternal medicinemedicineHumansCD40 AntigensPhytohemagglutininsCells CulturedAgedAged 80 and overCD40Membrane GlycoproteinsInterleukin-12EndocrinologyCytokinechemistryImmunologyInterleukin 12biology.proteinLeukocytes MononuclearFemaleMitogensDevelopmental BiologyMechanisms of ageing and development
researchProduct

Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

2005

Background: Interleukin (IL)-12p70 and IL-23 are key T helper-1 (TH1) cytokines that drive the inflammation seen in numerous models of intestinal inflammation. These molecules contain an identical p40 chain that is bound to a p35 chain in IL-12 and a p19 chain in IL-23, making both potentially susceptible to modulation by an anti-IL-12p40 monoclonal antibody (mAb). Methods: In the present study, we sought to determine whether active inflammation in Crohn's disease (CD) is associated with the increased synthesis of both of these cytokines and whether patients treated with an anti-IL-12p40 mAb down-regulate IL-23 as well as IL-12p70 as previous reported. Results: To this end we initially dete…

AdultMaleAdolescentBiopsyT-Lymphocytesmedicine.medical_treatmentT cellDown-RegulationInterleukin-23Crohn DiseaseInterleukin 23medicineHumansImmunology and AllergyCells CulturedAgedLamina propriaMucous MembraneCD40biologyInterleukin-12 Subunit p40Interleukin-6InterleukinsMacrophagesGastroenterologyAntibodies MonoclonalInterleukinMiddle AgedInterleukin-12Protein Subunitsmedicine.anatomical_structureCytokineImmunologyInterleukin-23 Subunit p19biology.proteinInterleukin 12FemaleTumor necrosis factor alphaInterleukin-1Inflammatory Bowel Diseases
researchProduct

Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behçet's disease: evidence for expansion, and tumour necrosis factor receptor II and interleuk…

2002

Behçet's disease is a multisystem disease in which there is evidence of immunological dysregulation. It has been proposed that gamma/delta T cells are involved in its pathogenesis. The aim of the present study was to assess the capacity of gamma/delta T cells with phenotype Vgamma9/Vdelta2, from a group of Italian patients with Behçet's disease, to proliferate in the presence of various phosphoantigens and to express tumour necrosis factor (TNF) and IL-12 receptors. Twenty-five patients and 45 healthy individuals were studied. Vgamma9/Vdelta2 T cells were analyzed by fluorescence activated cell sorting, utilizing specific monoclonal antibodies. For the expansion of Vgamma9/Vdelta2 T cells, …

AdultMaleBehçet's diseaseBehcet SyndromeT-LymphocytesReceptors Interleukin-12Receptors Antigen T-Cell gamma-deltaReceptors InterleukinMiddle AgedLymphocyte Activationγ/δ T lymphocyteReceptors Tumor Necrosis FactorPhenotypetumour necrosis factorItalyHumansFemaleinterleukin 12Cell DivisionCells CulturedResearch ArticleArthritis researchtherapy
researchProduct

Polymorphisms of microRNA target genes

2016

AIM To evaluate associations between miRNA target genes IL12B, INSR, CCND1 and IL10 polymorphisms and gastric cancer (GC) in European population. METHODS Gene polymorphisms were analyzed in 508 controls and 474 GC patients from 3 tertiary centers in Germany, Lithuania and Latvia. Controls were patients from the out-patient departments, who were referred for upper endoscopy because of dyspeptic symptoms and had no history of previous malignancy. Gastric cancer (GC) patients had histopathological verification of gastric adenocarcinoma. Genomic DNA was extracted using salting out method from peripheral blood mononuclear cells. IL12B T>G (rs1368439), INSR T>C (rs1051690), CCND1 A>C (rs7177) and…

AdultMaleGenotypeInterleukin-12 Subunit p40LithuaniaMiddle AgedCase Control StudyLatviaPolymorphism Single NucleotideSingle-nucleotide polymorphismsReceptor InsulinInterleukin-10Antigens CDStomach NeoplasmsCase-Control StudiesGermanyLeukocytes MononuclearHumansRegression AnalysisCyclin D1FemaleTarget genesGastric cancerAgedmiRNAWorld journal of gastroenterology
researchProduct

In vitro treatment with interleukin-2 normalizes type-1 cytokine production by lymphocytes from elderly

2000

The term immunosenescence is taken to mean the deterioration of immune function seen in elderly, which is manifested in increased susceptibility to infectious diseases, neoplasias, and autoimmune diseases. It is only recently that we have begun to understand the cellular and molecular changes involved. Of special interest in this regard are observations of a decline in synthesis of Type-1 cytokines which predisposes to diminished cell mediated immunity. We have evaluated the production of type 1 cytokines in old and young donors either in presence or in absence of recombinant interleukin-2 (rIL-2). Lymphocytes were stimulated with plastic bound anti-CD3 and after 48 h the supernatants were …

AdultMaleInterleukin 2Agingmedicine.medical_specialtymedicine.medical_treatmentImmunologyIn Vitro TechniquesBiologyToxicologylaw.inventionInterferon-gammaImmune systemlawInternal medicinemedicineHumansImmunology and AllergyAgedAged 80 and overPharmacologyGeneral MedicineImmunosenescenceMiddle AgedTh1 CellsInterleukin-12Recombinant ProteinsCell mediated immunityIn vitroEndocrinologyCytokineImmunologyRecombinant DNACytokinesInterleukin-2Femalemedicine.drug
researchProduct

Anti–Interleukin-12 Antibody for Active Crohn's Disease

2004

Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses.This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, an…

AdultMalemedicine.medical_specialtyColonmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodInternal medicinemedicineClinical endpointBriakinumabHumansAgedAged 80 and overCrohn's diseasebiologybusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseInterleukin-12digestive system diseasesCytokinechemistryImmunologyCohortLeukocytes MononuclearInterleukin 12biology.proteinCytokinesFemaleAntibodybusinessNew England Journal of Medicine
researchProduct